Macrogenics (FRA:M55) Days Inventory : 50.87 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Macrogenics's Average Total Inventories for the three months ended in Dec. 2024 was €2.9 Mil. Macrogenics's Cost of Goods Sold for the three months ended in Dec. 2024 was €5.2 Mil. Hence, Macrogenics's Days Inventory for the three months ended in Dec. 2024 was 50.87.

The historical rank and industry rank for Macrogenics's Days Inventory or its related term are showing as below:

FRA:M55' s Days Inventory Range Over the Past 10 Years
Min: 36.24 Med: 101.81 Max: 604.16
Current: 46.85

During the past 13 years, Macrogenics's highest Days Inventory was 604.16. The lowest was 36.24. And the median was 101.81.

FRA:M55's Days Inventory is ranked better than
88.35% of 644 companies
in the Biotechnology industry
Industry Median: 177.565 vs FRA:M55: 46.85

Macrogenics's Days Inventory declined from Dec. 2023 (648.85) to Dec. 2024 (50.87).

Inventory Turnover measures how fast the company turns over its inventory within a year. Macrogenics's Inventory Turnover for the three months ended in Dec. 2024 was 1.79.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Macrogenics's Inventory-to-Revenue for the three months ended in Dec. 2024 was 0.17.

Macrogenics Days Inventory Historical Data

The historical data trend for Macrogenics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Days Inventory Chart

Macrogenics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Inventory

Get a 7-Day Free Trial

604.13

137.52

60.27

34.80

Macrogenics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Inventory	Get a 7-Day Free Trial															648.85	53.15	38.00	107.20	50.87

Competitive Comparison of Macrogenics's Days Inventory

For the Biotechnology subindustry, Macrogenics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macrogenics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Macrogenics's Days Inventory falls into.

Save Embed

;

Save Embed

;

Macrogenics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Macrogenics's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as

	Days Inventory (A: Dec. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2023 )	+	Total Inventories (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (1.12	+	0)	/	1 )	/	11.746	*	365
=	1.12					/	11.746	*	365
=	34.80

Macrogenics's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:

	Days Inventory (Q: Dec. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2024 )	+	Total Inventories (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (2.923	+	0)	/	1 )	/	5.243	*	365 / 4
=	2.923					/	5.243	*	365 / 4
=	50.87

Macrogenics (FRA:M55) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Macrogenics's Inventory Turnover for the three months ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	5.243	/	2.923
	=	1.79

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Macrogenics's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	2.923	/	16.932
	=	0.17

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Macrogenics Days Inventory Related Terms

Thank you for viewing the detailed overview of Macrogenics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Macrogenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

MGNX:USA

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Macrogenics Headlines

No Headlines